Key Takeaways
- The change in administration and Republican control of the Senate raises several issues for industry, including drug pricing policies, M&A oversight, the Biosecure Act and Trump’s threats to levy steep tariffs on imports.
- Leadership at the FDA and HHS could be a concern, but changes at the FTC could be welcomed as potentially more friendly to mergers and acquisitions.
- The last Trump administration targeted drug pricing, but another area of uncertainty is what will happen to Medicare price negotiation under the IRA and whether new policies will be considered.
The election of Republican Donald Trump as the next president of the US could suggest a smoother road ahead for pharmaceutical manufacturers when it comes to drug pricing policies and mergers and acquisitions, but an administration friendlier to pharma is not a guarantee and Trump’s bombastic rhetoric
Drug manufacturers have a host of important issues that will be impacted by a change in administration and a Republican-controlled Senate, including drug pricing policies, M&A oversight, the fate of the Biosecure Act and Trump‘s threats to levy steep tariffs on imports, which could include active pharmaceutical ingredients (APIs). There are also concerns about the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?